Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
39.68
-1.53 (-3.71%)
At close: Jan 2, 2026, 4:00 PM EST
39.97
+0.29 (0.73%)
After-hours: Jan 2, 2026, 7:25 PM EST
Dianthus Therapeutics Employees
Dianthus Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 25 or 47.17% compared to the previous year.
Employees
78
Change (1Y)
25
Growth (1Y)
47.17%
Revenue / Employee
$39,462
Profits / Employee
-$1,619,808
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNTH News
- 10 days ago - Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics to Participate in Four Investor Conferences During November - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - GlobeNewsWire
- 4 months ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire